Immunotherapeutic Approaches in Triple-Negative Breast Cancer: State of the Art and Future Perspectives.

Int J Breast Cancer · 2020 · PMC7661147 · PMID 33204535

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Additionally, the pembrolizumab arm also showed a favorable trend in EFS (HR = 0.63 [95% CI 0.43-0.93]).

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.